We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How do people find these nuggets, impressive
Posted from Casanova labhttps://link.springer.com/article/10.1007/s10875-024-01708-7
Good to see they are cutting costs.
Should have done it earlier and they should have informed us more but we all know this company doesnt care about its small investors.
As a result they have benefitted traders like me over LTH that stumped up the money. Sad but true...
Enough looking back. Lets make money together ;)
Did we renew the photocopier deal at the same time?
I guess the trolls are wrong and we are not closing down then.
Poor Mr Costs will have to find some other angle to cry about
Behave Tommy.
This company is a disgrace and you know it.
When I read the headline I thought
Professional and Mr Costs had left
They are leaving a sinking ship
Sounds like the company is closing down?
Thank you captaincal.
I note that Hazel Pitt, the Director of Quality at Synairgen since Dec 2022, also has “#Open to Work” attached to her LinkedIn profile.
It would appear that Synairgen’s (undisclosed) strategy has evolved over the last two years or so. This is reflected by the recent gradual slimming down and reorganisation of the senior leadership team. The appointment of a CMO appears to have been a significant development.
Providing they can keep the P2 trials on track, without having to resort to additional funding, we have every chance of moving towards something of a recovery this year. In my view, it will take a liaison with a significant external partner to achieve anything near to the MCap reached during early 2022.
I am not pinning any hopes on a recovery until I am fully aware of what has been going on behind the scenes over the last seven months.
GLALTIs.
Sounds like it might be worth staying over - had to fly back last time!
Will be good to catch up with you again at and post the AGM Doc, Wigster, Bob & Jinty
Ditto all. Looking forward to the catch-up...I have a feeling that the post-AGM social / "put the world to rights" event could be more successful than the AGM itself :-)
Hi bobfraeberks,
Yes see you there (AGM).
Bob - in that case, we'll definitely see you there!!! ;)
Hi Jint. Many thanks for the highly informative update on the IP. We're still well in the game.
See you soon at the AGM (assuming it doesn't clash with the Scotland team dominating EURO24!!!). Cheers.
Forgive me for not having confidence in the company, of course they have a clear plan.
I should be more trusting of the directors when considering the following:
SNG not used in trials since Nov 2021.
CEO not providing updates.
Delayed new trials from RNS in 2022.
MCAP from £230M to 10M.
Of course, the directors have got a clear plan!
MrCosts
They’ve already laid out their clear plan and vision with the announced Phase2 trials, we are just awaiting the get go.
My 'down beat view' could be changed if the company actually updated shareholders with a clear plan and vision.
MrCosts
You have a very down beat view on the Company’s prospects for the future development of SNG001.
I personally take a different view on potential timeframes with SNG’s planned Phase2 trials and patient stratification that favours SNG001.
Yes there’s still much to be accomplished however, with successful Phase2 trials and interest via J/V or other, the process (Phase3) to authorisation time wise could be expedited sooner than the ‘at least 3-4 years’ that you are suggesting.
Lastly, of course the company are eager to accomplish authorisation, why wouldn’t they be?
In the world of therapeutic development, timings don’t always run to perceived schedules. Planning trials is complexed, involving and relying on many governmental agencies outside their control, it will take time and patience.
Summary:
Using a novel protein-structure-based B cell epitope discovery method with a wide range of possible applications, we have identified a simple to measure host-pathogen antibody signature associated with severe COVID-19 and longCOVID and suggest the viral Membrane protein contains an epitope that acts as a T independent antigen during infection triggering extrafollicular B cell activation.
Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
https://www.medrxiv.org/content/10.1101/2022.07.11.22277368v4
Jint - I appreciate your clear intent for positive news.
Authorisation? We are at least 3-4 years away from this IF we get some luck on along the way.
New phase 2 trials discussed in 2022 haven't even started which will involve around 100 patients. Who is approving the drug at that stage? This company appears to be no rush to obtain authorisation.
Sadly, this company remains research company, no commercial activity ever in their 22+ year history.